United States:
Podcast: What's New In Washington: What Congress Is Doing About Drug Pricing And Surprise Medical Billing
27 November 2019
Akin Gump Strauss Hauer & Feld LLP
To print this article, all you need is to be registered or login on Mondaq.com.
In this episode, Akin Gump health care and life sciences senior
counsel
Taylor Jones and public law and policy senior policy advisor
Julie Nolan discuss draft legislation currently on Capitol Hill
focusing on drug pricing and surprise medical billing.
Among the topics covered:
- What's driving legislation?
- Which draft bills have the most
support?
- What role does the international
pharmaceutical market play?
- What impact will impeachment
proceedings have?
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
FDA Ramps Up Actions On PFAS
Holland & Knight
The U.S. Food and Drug Administration (FDA) has increased regulatory activity with regard to per- and polyfluoroalkyl substances (PFAS).
Planning For The BIOSECURE Act
Foley Hoag LLP
Bipartisan legislation moving through the U.S. House and Senate, known as the BIOSECURE Act, could limit the ability of U.S. life sciences companies...